ArticleTranslational lung cancer research2026
Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have improved survival in non-small cell lung cancer (NSCLC), yet identifying who benefits from treatment remains difficult. Low skeletal muscle mass (SMM) is associated with poor cancer outcomes. We aim to examine the relationship between computed tomography (CT)-assessed sarcopenia and patient trajectories [death, immune-related adverse events (irAEs) and death after irAEs] following ICI initiation. Methods: We conducted a retrospective cohort study of NSCLC patients treated with ICIs at the University Medical Center Groningen [2015-2021] with baseline low-dose computed tomography (LDCT) scans. Sarcopenia was defined using sex-specific SMM thresholds. Multi-state time-to-event models estimated transition probabilities between ICI initiation and three outcomes: direct mortality (without irAEs), development of irAEs, and mortality after irAEs. Models were adjusted for age, sex, performance status, cancer stage, treatment line, body mass index (BMI), and combination therapy. Separate models were built for severe and any-grade irAEs. Results: Among 363 patients (96-month follow-up), 301 (82.9%) died and 166 (45.7%) developed irAEs, including 76 (20.9%) with severe irAEs. In the severe irAE model, sarcopenia was not associated with developing severe irAEs [hazard ratio (HR) =0.81, 95% confidence interval (CI): 0.42-1.58] or with mortality without severe irAEs (HR =1.19, 95% CI: 0.82-1.74). However, sarcopenia was associated with reduced mortality after severe irAEs (HR =0.39, 95% CI: 0.23-0.65). In the any-grade irAEs model, sarcopenic patients were less likely to develop irAEs (HR =0.63, 95% CI: 0.42-0.93). Sarcopenia was not linked to mortality without irAEs (HR =1.08, 95% CI: 0.70-1.67) or after any-grade irAEs (HR =0.81, 95% CI: 0.52-1.26). Conclusions: In this NSCLC cohort, CT-assessed sarcopenia was not associated with direct mortality without irAEs but was linked to a lower likelihood of developing irAEs and reduced mortality after severe irAEs. These findings suggest that body composition may have prognostic value and influence responses to immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.